This is an aggregated industry headline. Read the full story at FierceBiotech →
Merck's $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
A phase 2 trial of Merck & Co.'s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback was offset by a midphase win in another indication.
By FierceBiotech
· Aug 4, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen's flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive car…
The WeekFierceBiotech ↗
Contract research organization Icon announced a multi-year collaboration with Anthropic this week to bring Cla…
The WeekBriefing
A new analysis challenged a controversial federal-law provision that exempts certain orphan drugs from Medicar…